Amgen’s Aflibercept And Aurobindo’s Pegfilgrastim Win EU Nods
As Accord Gets CHMP Positive Opinion For Eltrombopag Generic
In its first meeting of 2025, the EMA’s CHMP issued positive opinions recommending marketing authorizations for Eylea and Neulasta biosimilars from Amgen and Aurobindo, as well as a Revolade generic from Accord.
